ANTARES PHARMA WKN: 903128 ISIN: US0366421065 Kürzel: ATRS Forum: Aktien Thema: Hauptdiskussion
5,25 EUR
±0,00 %±0,00
24. May, 10:31:31 Uhr,
Berlin
Kommentare 166
K
KiMeSi,
13.04.2022 16:16 Uhr
0
👍
K
KiMeSi,
13.04.2022 15:55 Uhr
0
Hallo was sind das für Spielsachen
Yakuzzi05,
13.04.2022 13:39 Uhr
0
Läuft endlich mal, geil 🤩
Summer.76,
13.04.2022 13:26 Uhr
0
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
https://www.prnewswire.com/news-releases/halozyme-to-acquire-antares-pharma-to-create-a-specialty-product-and-drug-delivery-leader-301524604.html
Summer.76,
29.03.2022 14:36 Uhr
0
Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy
https://www.globenewswire.com/news-release/2022/03/29/2411744/35385/en/Antares-Pharma-Announces-FDA-Approval-Of-TLANDO-an-Oral-Treatment-for-Testosterone-Replacement-Therapy.html
Commercial launch expected in 2Q 2022
Summer.76,
03.03.2022 13:33 Uhr
0
Antares Pharma Non-GAAP EPS of $0.02 beats by $0.01, revenue of $48.73M beats by $1.54M
https://seekingalpha.com/news/3808993-antares-pharma-non-gaap-eps-of-0_02-beats-0_01-revenue-of-48_73m-beats-1_54m
Antares Pharma press release (NASDAQ:ATRS): Q4 Non-GAAP EPS of $0.02 beats by $0.01.
Revenue of $48.73M (+10.5% Y/Y) beats by $1.54M.
The Company today provided its full-year 2022 revenue guidance range of $200 to $220 million, which does not include any unapproved products and assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic. Excluding 2021 OTREXUP® proprietary revenue, the guidance range represents a 18% to 30% year-over-year growth rate vs. $211.38M consensus.
Summer.76,
03.03.2022 13:24 Uhr
0
Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results
https://www.globenewswire.com/news-release/2022/03/03/2396099/35385/en/Antares-Pharma-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-and-Operating-Results.html
Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million
Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share
Full-Year 2021 Adjusted EBITDA of $39.2 Million
2022 Revenue Guidance Range of $200 to $220 Million
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | GAMESTOP Hauptdiskussion | +0,59 % | |
2 | Brainchip Klassengruppe | ±0,00 % | |
3 | Neues DeFi Technologies Forum | ±0,00 % | |
4 | Cloudberry Clean | ±0,00 % | |
5 | BioNTech Hauptdiskussion | -1,40 % | |
6 | PowerTap Hydrogen Capital Corp Registered Shs Hauptdiskussion | +66,67 % | |
7 | ICADE Hauptdiskussion | ±0,00 % | |
8 | GECINA Hauptdiskussion | ±0,00 % | |
9 | DAX Hauptdiskussion | +0,13 % | |
10 | CoinBase (Future ExChange) | ±0,00 % | Alle Diskussionen |
Anzeige
Aktien
|
Thema | ||
---|---|---|---|
1 | GAMESTOP Hauptdiskussion | +0,59 % | |
2 | Brainchip Klassengruppe | ±0,00 % | |
3 | Neues DeFi Technologies Forum | ±0,00 % | |
4 | Cloudberry Clean | ±0,00 % | |
5 | BioNTech Hauptdiskussion | -1,40 % | |
6 | PowerTap Hydrogen Capital Corp Registered Shs Hauptdiskussion | +66,67 % | |
7 | ICADE Hauptdiskussion | ±0,00 % | |
8 | GECINA Hauptdiskussion | ±0,00 % | |
9 | CoinBase (Future ExChange) | ±0,00 % | |
10 | ALBEMARLE Hauptdiskussion | ±0,00 % | Alle Diskussionen |